Özet PDF Benzer Makaleler Yazara Mail Gönder

¹Sağlık Bilimleri Üniversitesi Gaziosmanpaşa Eğitim ve Araştırma Hastanesi, Beyin ve Sinir Cerrahisi Kliniği, İstanbul, Türkiye Traumatic spinal cord injury has an incidence of 10.4-83 cases/million/year worldwide and is an important cause of morbidity with a high material and moral burden in the society. Despite the better understanding of the pathophysiology today, the clinical use of neuroprotective and neuronal regrowth or neuroregenerative approaches aimed at preventing cord injury in the treatment has been limited to date. Current management strategies in recent studies include early surgical decompression and fixation, the use of vasopressor drugs to increase the mean arterial pressure and improve spinal perfusion, and treatment with methylprednisolone, amantadine, thyylazad mesylate, naloxone, thyrotropin releasing hormone, minocycline, glyburide, magnesium, granulocyte factor and neuroprotective agents such as glycicidine, as well as myelin-related inhibitors (eg Anti-Nogo antibodies [ATI-355]) aimed at increasing neural regeneration, such as the Rho inhibitor VX-210/ Cethrin, gangliosides, fibroblast growth factor, and stem cell transplantation. Current methods of pharmacological treatment have been reviewed with the literature. Anahtar Kelimeler : Pharmacological treatment, Stem cells, Neuroregenerative, Neuroprotective, Traumatic spinal cord injury